Seeking Alpha

YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study...

YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study of its CYT387 drug for treating myleofibrosis, both with regards to efficacy and safety. The company hopes to start "pivotal trials" for the drug in mid-2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs